Ingevity (NYSE:NGVT) CEO David Li Sells 5,000 Shares of Stock

Ingevity Corporation (NYSE:NGVT) CEO David Li sold 5,000 shares of Ingevity stock in a transaction on Monday, August 17th. The stock was sold at an average price of $75.83, for a total transaction of $379,150.00. Following the sale, the chief executive officer owned 120,636 shares of the company’s stock, valued at $9,147,827.88. The trade was a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ingevity Price Performance

NYSE NGVT opened at $74.01 on Wednesday. The company has a debt-to-equity ratio of 22.52, a current ratio of 1.61 and a quick ratio of 1.15. The stock’s fifty day moving average price is $73.84 and its 200 day moving average price is $71.78. Ingevity Corporation has a 1 year low of $45.85 and a 1 year high of $79.29. The company has a market cap of $2.54 billion, a price-to-earnings ratio of 50.34 and a beta of 1.16.

Ingevity (NYSE:NGVT) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $1.74 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.41. The company had revenue of $314.10 million during the quarter, compared to analysts’ expectations of $312.20 million. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. As a group, equities research analysts forecast that Ingevity Corporation will post 5.4 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of NGVT. Global Retirement Partners LLC acquired a new stake in shares of Ingevity during the 4th quarter worth approximately $27,000. Frazier Financial Advisors LLC acquired a new position in shares of Ingevity in the 2nd quarter valued at $37,000. Meeder Asset Management Inc. purchased a new stake in Ingevity during the fourth quarter worth $33,000. Kestra Advisory Services LLC acquired a new stake in Ingevity during the fourth quarter valued at $47,000. Finally, Geneos Wealth Management Inc. grew its position in Ingevity by 85.8% during the second quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock valued at $36,000 after buying an additional 387 shares during the period. 91.59% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NGVT has been the subject of a number of recent research reports. Wall Street Zen lowered shares of Ingevity from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 1st. Weiss Ratings raised shares of Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, July 31st. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $80.00.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.